<DOC>
	<DOC>NCT00542893</DOC>
	<brief_summary>This clinical drug-drug interaction study is being conducted to evaluate the pharmacokinetics of dacarbazine(DTIC) when administered in combination with Genasense</brief_summary>
	<brief_title>A Phase I, Randomized, Open-label, Cross-over, Pharmacokinetic Study of Genasense With and Without Dacarbazine</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Metastatic Stage IV disease, or Stage III disease that is not surgically resectable ECOG Performance Status of 0, 1, or 2 Life expectancy of at least 12 weeks Adequate venous access Agreement to practice effective method of birth control Less than 3 weeks of recovery from prior major surgery or other therapy, including radiation therapy, chemotherapy, or immunotherapy, or cytokine, biologic, or vaccine therapy Significant medical disease Known hypersensitivity to phosphorothioatecontaining oligonucleotides Known hypersensitivity to DTIC Pregnancy/Lactation</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>bcl-2</keyword>
	<keyword>CFR</keyword>
	<keyword>DTIC</keyword>
	<keyword>ECOG</keyword>
	<keyword>EMEA</keyword>
	<keyword>MedDRA</keyword>
	<keyword>NCI CTC</keyword>
	<keyword>SAE</keyword>
</DOC>